Therapeutic drug monitoring

Determination of free therapeutic certolizumab

Certolizumab is the Fab’ fragment of a recombinant humanised antibody conjugated to polyethylene glycol (PEG) and is therefore also known as “certolizumab pegol”. The IDKmonitor Certolizumab Drug Level ELISA kit is a microplate-based quantitative enzyme linked immunosorbent assay (ELISA) for the determination of free certolizumab therapeutic drug in serum and EDTA plasma samples.

Ustekinumab is a fully humanised IgG1 therapeutic monoclonal antibody used for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis. This assay enables the reliable determination of free, unbound anti-drug antibodies.

Ustekinumab is a fully humanised IgG1 therapeutic monoclonal antibody used for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis. This drug-tolerant assay enables the reliable determination of anti-drug antibodies even in the presence of ustekinumab.

The IDKmonitor Vedolizumab Free Anti-drug ELISA kit is a microplate-based quantitative sandwich ELISA for the determination of free anti-vedolizumab antibodies in plasma or serum samples. Detecting high levels of free anti-vedolizumab antibodies in patients when the drug level is low (undetectable or sub-therapeutic) may indicate poorer long-term outcomes and suggest the need to switch treatment.

The IDKmonitor Rituximab Drug Level ELISA kit is a microplate-based quantitative assay for the determination of free rituximab from plasma or serum samples. Rituximab is a chimeric therapeutic monoclonal antibody (mAb) that targets B-cells (CD-20) in the treatment of rheumatoid arthritis, non-Hodgkin’s B-cell lymphomas, lymphocytic leukaemia, active granulomatosis with polyangiitis and microscopic polyangiitis.

Vedolizumab is a recombinant protein used to treat Crohn’s disease and ulcerative colitis. The IDKmonitor Vedolizumab Drug Level ELISA kit is a microplate-based quantitative enzyme linked immunosorbent assay (ELISA) for the determination of free vedolizumab in plasma or serum samples.

Ustekinumab is a recombinant protein used to treat inflammatory bowel disease (IBD). The IDKmonitor Ustekinumab Drug Level ELISA kit is a microplate-based quantitative enzyme linked immunosorbent assay (ELISA) for the determination of free ustekinumab in plasma or serum samples.

Infliximab is a recombinant protein used to treat inflammatory bowel disease (IBD). This protein can induce humoral immune responses and lead to anti-drug antibody formation, which is a major cause of loss of drug response. The IDKmonitor Infliximab Total Anti-drug ELISA kit is a ‘drug tolerant’ assay that enables the detection of anti-drug antibodies in the presence of circulating drug.

Infliximab is a recombinant protein used to treat inflammatory bowel disease (IBD). The IDKmonitor Infliximab Drug Level ELISA kit is a microplate-based quantitative enzyme linked immunosorbent assay (ELISA) for the determination of free infliximab in plasma or serum samples.

Golimumab is a recombinant protein used to treat inflammatory bowel disease (IBD). The IDKmonitor Golimumab Drug Level ELISA kit is a microplate-based quantitative enzyme linked immunosorbent assay (ELISA) for the determination of free golimumab in plasma or serum samples.

IDKmonitor Etanercept Free Anti-drug Antibody ELISA is a quantitative assay that detects human antibodies against etanercept in EDTA plasma and serum samples. Etanercept is a human therapeutic monoclonal antibody used to monitor treatment for chronic rheumatic diseases such as rheumatoid arthritis.

The innovative IDKmonitor Etanercept Drug Level ELISA is a microplate-based assay that allows quantitative determination of free etanercept from plasma or serum samples. Etanercept is a human therapeutic monoclonal antibody (mAb) used to monitor treatment for chronic rheumatic diseases such as rheumatoid arthritis.

Adalimumab is a recombinant protein used to treat inflammatory bowel disease (IBD). This protein can induce humoral immune responses and lead to anti-drug antibody formation, which is a major cause of loss of drug response. The IDKmonitor Adalimumab Total Anti-drug ELISA kit is a ‘drug tolerant’ assay that enables the detection of anti-drug antibodies in the presence of circulating drug.

Adalimumab is a recombinant protein used to treat inflammatory bowel disease (IBD). The IDKmonitor Adalimumab Drug Level ELISA kit is a microplate-based quantitative sandwich ELISA for the determination of free therapeutic TNFα antibodies (adalimumab) from plasma or serum samples.

Infliximab is a recombinant protein used to treat inflammatory bowel disease (IBD). This protein can induce humoral immune responses and lead to anti-drug antibody formation which is a major cause of loss of drug response.

Golimumab is a recombinant protein used to treat inflammatory bowel disease (IBD). This protein can induce humoral immune responses and lead to anti-drug antibody formation, which is a major cause of loss of drug response.

Adalimumab is a recombinant protein used to treat inflammatory bowel disease (IBD). This protein can induce humoral immune responses and lead to anti-drug antibody formation, which is a major cause of loss of drug response.

The IDK Oncostatin M (OSM) ELISA is used for the quantitative determination of oncostatin M in serum, plasma or stools. OSM and its receptor, OSMR, are involved in gut inflammation, and are upregulated in the mucosa of IBD patients.